2026-04-18T03:00:28Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1649992025-12-05T04:24:18Zcom_2072_1057col_2072_478809col_2072_478917

00925njm 22002777a 4500 dc Darbà, Josep author Ascanio, Meritxell author Carvalho, Davide author Conde, Vasco author Pedersen, Kasper S. author 2020-06-10T08:05:43Z 2020-12-20T06:10:18Z 2019-12-20 2020-06-10T08:05:43Z Objectives: To assess the cost-effectiveness of insulin degludec (degludec) versus insulin glargine (glargine) U100 from a Portuguese healthcare perspective using data from SWITCH 1 & 2 trials. - - - Methods: A short-term model estimated cost-effectiveness of degludec versus glargine U100 in type 1 diabetes (T1DM) basal bolus (B/B) and type 2 diabetes (T2DM) basal oral therapy (BOT) patients. The model captured hypoglycaemia rates and insulin dosing. Clinical outcomes were obtained from SWITCH 1 & 2. Disutilities related to hypoglycaemic events and insulin, needles and blood glucose tests costs were also included. Benefits were measured in QALYs. One-way and probabilistic sensitivity analyses were conducted (...) Anàlisi cost-benefici Salut pública Diabetis Insulina Portugal Cost effectiveness Public health Diabetes Insulin Portugal Cost-effectiveness of insulin degludec versus insulin glargine U100 in patients with type 1 and type 2 diabetes in Portugal: evidence from SWITCH 1&2 trials